Skip to main content
    H

    Humacyte Inc (HUMA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.54
    -0.02 (-3.24%)

    Market Cap: $155.12M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Humacyte Inc (HUMA) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Humacyte (HUMA) trades at 62.6x sales and 8.3x book value. Its P/B of 8.3x is above its 5-year median of 6.2x. Its forward P/E is 35.8x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E35.8x
    Price to sales62.6x
    Price to book8.3x
    PEGN/A
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/B8.3x6.2xN/A
    Medians of month-end values through Oct 2026: 48 months (5-year).

    Valuation History

    Over the 4 of the 5 year ends shown that have a P/S, its P/S ranged from 27.3x in 2023 to 138.9x in 2022.

    Year endPriceP/SP/B
    2025$0.9670.7x48.9x
    2024$5.0582.8xN/A
    2023$2.8427.3x21.7x
    2022$2.11138.9x1.9x
    2021$7.25N/A6.2x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    Frequently Asked Questions About HUMA

    What is HUMA's forward P/E ratio?

    Humacyte has a forward P/E ratio of 35.8x.

    What is HUMA's price to sales ratio?

    Humacyte has a price to sales ratio of 62.6x.